Advertisement
Canada markets close in 29 minutes

  • S&P/TSX

    21,791.14
    +82.70 (+0.38%)
     

  • S&P 500

    4,967.43
    -43.69 (-0.87%)
     

  • DOW

    37,953.52
    +178.14 (+0.47%)
     

  • CAD/USD

    0.7274
    +0.0010 (+0.14%)
     

  • CRUDE OIL

    83.26
    +0.53 (+0.64%)
     

  • Bitcoin CAD

    88,501.79
    +1,388.17 (+1.59%)
     

  • CMC Crypto 200

    1,383.70
    +71.08 (+5.42%)
     

  • GOLD FUTURES

    2,409.80
    +11.80 (+0.49%)
     

  • RUSSELL 2000

    1,939.40
    -3.56 (-0.18%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,287.39
    -314.11 (-2.01%)
     

  • VOLATILITY

    18.96
    +0.96 (+5.34%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

Why Advaxis Stock Is Soaring Today

Daniel Collins
Updated
Why Advaxis Stock Is Soaring Today

Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22. On July 12, Advaxis stock closed at $1.22 and hit its 52-week low of $1.15. Advaxis hit its 52-week high of $7.45 on September 11, 2017. Today, the FDA lifted its clinical hold on Advaxis’s IND (Investigational New Drug) application for the initiation of its Phase 1/2 trial of a combination therapy of axalimogene filolisbac and AstraZeneca’s (AZN) Imfinzi (duravalumab).

Continue reading